Merge branch 'main' of ssh://gitlab.igem.org/2024/bielefeld-cebitec

src/contents/Human Practices/Further Engagement/Education.tsx

@@ -38,9 +38,10 @@ Due to our collaboration with the Student Academy, we conducted the nanopore seq
                     <H5 id="Der Teuto ruft!" text=" What is “Der Teuto ruft!” and why we participate"/>
                     <p></p>
                 </div>
-                
 
 <p></p>
+<p>"Der Teuto ruft!" is an outreach event located all over the city of Bielefeld where various local companies and institutions engage with the public to inform them about their work. Since we wanted to raise awareness for cystic fibrosis and present our approach to developing an optimized gene therapy to combat this disease, our participation in the "Der Teuto ruft!" event in Bielefeld was the perfect opportunity to do so.</p>               
+<H5 id="What was our strategy?" text="What is our strategy?"/>
 <p>Our goal was to educate children about the challenges faced by CF patients, especially the ones with lung problems. The knowledge which we gained at the Science Communication Workshop as part of the BFH Meetup was the optimal basis to plan our outreach to the public. We engaged the children with activities like coloring lung images and conducting experiments to experience and understand lung related symptoms.  
 One such experiment involved creating a lung model from balloons and straws, demonstrating the difficulty patients have in breathing by having the children blow into the straws. Additionally, we set up a tank with a mixture of starch and water to simulate mucus and placed a ball on top. The children tried to blow the ball across the surface, illustrating how hard it is for air to move through mucus compared to water, where the ball moved much more easily. 
 The very little ones could paint coloring pages which we designed and printed for them. For the adults, we provided information about our project and discussed the implications and potential of gene therapy for cystic fibrosis. These conversations made it abundantly clear that degrees of knowledge on this topic widely vary throughout the public and we were happy to fill in the existing gaps in people's knowledge and exchange points of view on gene therapy.  

src/contents/description.tsx

@@ -110,13 +110,13 @@ export function Description() {
                     </div>
                 </Subesction>
                 <Subesction title="Treatment" id="Cystic Fibrosis6">
-                    <img src="https://static.igem.wiki/teams/5247/placeholders/placehilderperson.jpeg"/> 
+                    <p>Cystic fibrosis therapy means inevitably a complex and customized treatment plan for each patient. It consists of a range of components. These include medication such as CFTR modulators and antibiotics as well as inhalation therapy and mucolytics, physiotherapy, nutritional therapy and sports therapy. It is therefore essential that CF patients receive treatment at a specialist centre [1].</p>
                     <Collapsible id="drugs-collapsible" title="Different types of drugs" >
                     <TabButtonRow data={medibuttonrowdata} opentype="symptabs" closing=""/>
                     <ButtonRowTabs data={medibuttonrowdata} cla="symptabs"/>
                     </Collapsible>
-                    <H2 text="The future of CF treatment with gene therapy"></H2>
-                    <p> While mentioned medications have improved the quality of life for numerous CF patients, they only manage symptoms rather than cure the disease. Moreover, most of them are expensive and not world-wide accessible. Our research is focused on the development of a gene therapy that targets the underlying cause of CF by correcting the defective CFTR gene. <PreCyse/> aims to halt disease progression and reduce the treatment burden for patients."</p>
+                    <H2 text="CF treatment with gene therapy"></H2>
+                    <p>While mentioned medications have improved the quality of life for numerous CF patients, they only manage symptoms rather than cure the disease. Moreover, most of them are expensive and not world-wide accessible. Our research is focused on the development of a gene therapy that targets the underlying cause of CF by correcting the defective CFTR gene. <PreCyse/> aims to halt disease progression and reduce the treatment burden for patients.</p>
                     <img src="https://static.igem.wiki/teams/5247/charts-maps/cfper10-000.png"/> 
                 </Subesction>
             </Section>

src/contents/safety.tsx

@@ -103,7 +103,10 @@ export const Safety: React.FC = () =>{
         </p>
         <p>
         In our S2 laboratory, the harvested nasal epithelial cells that serve as primary cultures undergo a comprehensive HHH test (link zu primär Kulturen) to ensure their safety and suitability for further experiments. This test is crucial to ensure that we can subsequently work safely with these cells in the S1 range without the risk of contamination or unwanted release of biological material. 
-        </p> 
+        </p>
+        <div className="col">
+          <img src="https://static.igem.wiki/teams/5247/photos/biosafety/s2/s2-lab.jpeg"/>
+        </div>
       </Section>
       <Section title="Biosafety" id="Biosafety">
         <Subesction title="Mechanism" id="Biosafety1">